Related Experiment Video
Updated: Nov 3, 2025
05:13
Preclinical Model of Prenatal Delta-9-Tetrahydrocannabinol Exposure to Assess Its Impact on Neurodevelopmental Outcomes
Published on: February 28, 2025
437
Cannabidiol and Neurodevelopmental Disorders in Children
Keith A Kwan Cheung1, Murray D Mitchell1, Helen S Heussler2,3
1Centre for Children's Health Research, School of Biomedical Sciences, Faculty of Health, Queensland University of Technology, Brisbane, QLD, Australia.
Frontiers in Psychiatry
|June 7, 2021
Summary
Medicinal cannabis, particularly cannabidiol, shows promise for managing symptoms of neurodevelopmental disorders in children. Further research into cannabinoid mechanisms could unlock improved treatments for conditions like autism spectrum disorder.
Area of Science:
- Neuroscience
- Pharmacology
- Pediatrics
Background:
- Neurodevelopmental and neuropsychiatric disorders significantly impact children's health, often lacking definitive cures.
- Medicinal cannabis is emerging as a potential therapeutic option for symptom management and improved quality of life.
- Cannabidiol (CBD) is noted for its safety, tolerability, and anticonvulsant, anxiolytic, and anti-inflammatory properties.
Purpose of the Study:
- To explore the therapeutic potential of cannabinoids, specifically cannabidiol, for neurodevelopmental disorders.
- To investigate the role of the endocannabinoid system in neural development and health.
- To understand the mechanisms of action of cannabinoids for improved treatment strategies.
Main Methods:
- Review of recent clinical trials on medicinal cannabis for neurodevelopmental disorders.
- Analysis of preclinical and clinical data on cannabidiol's pharmacological properties.
- Examination of research on endocannabinoid system signaling pathways and neurotransmitter interactions.
Main Results:
- Cannabis-based treatments, especially cannabidiol, have shown success in managing symptoms and enhancing patient quality of life.
- Cannabidiol exhibits a favorable safety profile and therapeutic effects including anticonvulsant, anxiolytic, and anti-inflammatory actions.
- Evidence suggests the endocannabinoid system plays a critical role in neural development and health.
Conclusions:
- Cannabinoids, particularly cannabidiol, represent a promising avenue for treating neurodevelopmental disorders.
- Understanding the intricate signaling pathways between neurotransmitters and the endocannabinoid system is key.
- Further research into cannabinoid mechanisms can pave the way for more effective therapeutic interventions.
Related Concept Videos
01:24CNS Stimulants: Cocaine, Amphetamines and Cannabinoids
454
CNS stimulants, such as cocaine, amphetamines, and cannabinoids, have varying structures and mechanisms of action that lead to different therapeutic effects and side effects. Cocaine, with its molecular formula C17H21NO4, is a tropane alkaloid and a tertiary amino compound. It has two chemical forms: the hydrochloride salt and the "freebase." The former is in powder form, while the latter involves removing the hydrochloride salt to create a form that can be smoked. Cocaine exerts its...
454
01:30Attention-Deficit/Hyperactivity Disorder
481
Attention-deficit/hyperactivity disorder (ADHD) is a neurodevelopmental disorder characterized by persistent inattention, hyperactivity, and impulsivity. It affects approximately 5-8% of children globally, with around 60-70% of cases persisting into adulthood. ADHD has significant implications for educational attainment, social interactions, and occupational success.
Diagnostic Criteria and Symptoms
To diagnose ADHD, symptoms must manifest before age 12 and be evident across multiple settings....
Diagnostic Criteria and Symptoms
To diagnose ADHD, symptoms must manifest before age 12 and be evident across multiple settings....
481
01:21Chemotherapy-Induced Nausea and Vomiting: Cannabinoids
461
Tetrahydrocannabinol (THC) is a phytocannabinoid that primarily interacts with the CB1 receptor, a type of G protein-coupled receptor (GPCR) predominantly in and around the chemoreceptor trigger zone (CTZ) and emetic center. THC also blocks the serotonin receptor activity in the dorsal vagal complex (DVC) by inhibiting serotonin release. THC exerts its anti-emetic effects through these interactions, which are beneficial for patients undergoing chemotherapy.
Two synthetic agonists of THC,...
Two synthetic agonists of THC,...
461
01:29Drugs Affecting Neurotransmitter Synthesis
1.8K
Drugs affecting neurotransmitter synthesis can impact the adrenergic neuron and the synthesis of neurotransmitters. For example, α-methyltyrosine and carbidopa target specific enzymes involved in catecholamine synthesis. α-methyltyrosine inhibits the enzyme tyrosine hydroxylase, which converts tyrosine into dopamine. By blocking this enzyme, α-methyltyrosine reduces dopamine production and other catecholamines. Carbidopa, on the other hand, inhibits the enzyme dopa decarboxylase,...
1.8K
01:19Autism Spectrum Disorder
508
Autism spectrum disorder (ASD) is a neurodevelopmental condition marked by persistent deficits in social communication and interaction alongside restrictive and repetitive behaviors or interests. ASD is sometimes accompanied by intellectual impairment.
These core symptoms manifest differently among individuals, ranging from mild to severe. The disorder's complexity extends beyond its clinical presentation, encompassing a diverse range of biological, cognitive, and sociocultural influences.
These core symptoms manifest differently among individuals, ranging from mild to severe. The disorder's complexity extends beyond its clinical presentation, encompassing a diverse range of biological, cognitive, and sociocultural influences.
508
01:24Pharmacokinetics in Pediatric Patients: Drug Metabolism
48
In pediatric care, understanding the nuances of hepatic drug metabolism is crucial, as it significantly differs from that of adults. This divergence is primarily due to the developmental stage of drug-metabolizing enzymes, which affects how medications are processed in the body. In neonates, for instance, the activity of Phase I enzymes—critical for the initial breakdown of drugs—is markedly reduced, functioning at just 20–40% of the levels seen in adults. This reduction poses...
48